Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Receivables (2018 - 2025)

UroGen Pharma's Change in Receivables history spans 7 years, with the latest figure at $13.4 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 635.16% year-over-year to $13.4 million; the TTM value through Dec 2025 reached $12.8 million, up 163.02%, while the annual FY2025 figure was $12.8 million, 163.02% up from the prior year.
  • Change in Receivables reached $13.4 million in Q4 2025 per URGN's latest filing, up from $54000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $13.4 million in Q4 2025 to a low of -$2.7 million in Q3 2023.
  • Average Change in Receivables over 5 years is $1.3 million, with a median of $32500.0 recorded in 2025.
  • Peak YoY movement for Change in Receivables: tumbled 509.0% in 2024, then skyrocketed 635.16% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $3.9 million in 2021, then fell by 16.75% to $3.3 million in 2022, then dropped by 20.73% to $2.6 million in 2023, then plummeted by 196.3% to -$2.5 million in 2024, then surged by 635.16% to $13.4 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Change in Receivables are $13.4 million (Q4 2025), $54000.0 (Q3 2025), and $11000.0 (Q2 2025).